



THE AUSTRIAN ACADEMY OF SCIENCES & HASUMI INTERNATIONAL RESEARCH FOUNDATION

INTERNATIONAL CANCER VACCINE SYMPOSIUM

- 11:00 RALPH M. STEINMAN (ROCKEFELLER UNIVERSITY, NEW YORK, NY, USA)
„THE DENDRITIC CELL-NKT LYMPHOCYTE AXIS AS ADJUNCTS AND ADJUVANTS FOR IMMUNOTHERAPY“
- 11:30 EVELYN ULLRICH (INSTITUT GUSTAVE ROUSSY, VILLEJUIF, FRANCE) :
„A TWO STEP LINK BETWEEN INNATE AND COGNATE IMMUNITY: THE PIVOTAL ROLE OF IKDC“
- 12:00 GEORG STINGL (MEDICAL UNIVERSITY OF VIENNA, AUSTRIA):
„DENDRITIC CELLS – MORE THAN ANTIGEN-PRESENTING CELLS?“
- 12:30 LUNCH

SESSION 6: VARIA

- 14:00 RALPH A. REISFELD (THE SCRIPPS RESEARCH INSTITUTE, LA JOLLA, CA, USA):
„THE ROLE OF THE CANCER STROMA AS A TARGET OF A TUMORICIDAL IMMUNE RESPONSE“
- 14:30 ERIKA JENSEN-JAROLIM (MEDICAL UNIVERSITY OF VIENNA, AUSTRIA):
„MIMOTOPE VACCINATION - FROM ALLERGY TO CANCER“
- 15:00 HERMANN WAGNER (TECHNICAL UNIVERSITY MUNICH, GERMANY):
„PROTECTIVE CANCER IMMUNOTHERAPY - WHAT CAN THE INNATE IMMUNE SYSTEM CONTRIBUTE?“
- 15:30 COFFEE BREAK
- 16:00 REINHARD KIRNBAUER (MEDICAL UNIVERSITY OF VIENNA, AUSTRIA):
„DEVELOPMENT OF PREVENTIVE PAPILLOMAVIRUS CANCER VACCINES“
- 16:30 STEPHAN N. WAGNER (MEDICAL UNIVERSITY OF VIENNA, AUSTRIA):
„THE RENAISSANCE OF ANTIBODY-BASED CANCER THERAPY“

PANEL DISCUSSION: CAN WE CURE ONLY MICE?

- 17:00 HANS WIGZELL (KAROLINSKA INSTITUTE, STOCKHOLM, SWEDEN): CHAIR
- PIERRE COULIE (UNIVERSITÉ CATHOLIQUE DE LOUVAIN, BRUSSELS, BELGIUM)
- CORNELIS J.M. MELIEF (UNIVERSITY HOSPITAL LEIDEN, NETHERLANDS)
- JEFFREY S. WEBER (USC/NORRIS COMPREHENSIVE CANCER INSTITUTE, LOS ANGELES, CA, USA)

CLOSING REMARKS:

- 18.00 GEORG STINGL (MEDICAL UNIVERSITY OF VIENNA, AUSTRIA)
- KENICHIRO HASUMI (HASUMI INTERNATIONAL RESEARCH FOUNDATION)

ONLINE REGISTRATION:
WWW.CANCER-VACCINE-SYMPOSIUM.ORG

CONTACT:
 AUSTRIAN ACADEMY OF SCIENCES
 c/o MARIE-THERÈSE PORZER
 DR. IGNAZ SEIPEL-PLATZ 2
 A-1010 WIEN
 PHONE: (+43 1) 51581-1234
 E-MAIL: marie-therese.porzer@oeaw.ac.at

CANCER VACCINES: CAN WE CURE ONLY MICE?

CURRENT CLINICAL AND LABORATORY ADVANCES IN
 CANCER VACCINES AND IMMUNOTHERAPY

PROGRAM



CHAIRMEN: GEORG STINGL
DEAN L. MANN

THURSDAY APRIL 12, 2007

- 16:00 REGISTRATION
17:30 WELCOME
18:00 KEYNOTE LECTURE:
THOMAS A. WALDMANN (NATIONAL CANCER INSTITUTE, NIH, BETHESDA, MD, USA):
„IMMUNOTHERAPY OF HUMAN CANCER – A CRITICAL APPRAISAL“
19:00 RECEPTION AT THE AAS FOYER

FRIDAY APRIL 13, 2007

- 07:30 COFFEE AND REGISTRATION
SESSION 1: BASIC PRINCIPLES
08:30 WEIPING ZOU (UNIVERSITY OF MICHIGAN SCHOOL OF MEDICINE, ANN ARBOR, MI, USA):
„IMMUNE SUPPRESSIVE NETWORKS IN THE CANCER ENVIRONMENT - IMPACT ON IMMUNOTHERAPY“
09:00 CORNELIS J.M. MELIEF (UNIVERSITY HOSPITAL LEIDEN, NETHERLANDS):
„IMMUNE ESCAPE – HOW TO DEAL WITH IT?“
09:30 THOMAS BLANKENSTEIN (CHARITÉ CAMPUS BENJAMIN FRANKLIN, BERLIN, GERMANY):
„CANCER IMMUNOTHERAPY – DON'T FORGET THE STROMA!“
10:00 ANTONIO LANZAVECCHIA (INSTITUTE FOR RESEARCH IN BIOMEDICINE, BELLINZONA, SWITZERLAND):
„CENTRAL AND EFFECTOR MEMORY T-CELLS IN VACCINATION AND IMMUNOTHERAPY“
10:30 COFFEE BREAK
SESSION 2: QUANTITATIVE AND QUALITATIVE ASPECTS OF A BIOLOGICALLY RELEVANT T-CELL RESPONSE
11:00 PEDRO ROMERO (LUDWIG INSTITUTE FOR CANCER RESEARCH, LAUSANNE, SWITZERLAND):
„MONITORING THE QUANTITY AND QUALITY OF TUMOR ANTIGEN-SPECIFIC T-CELL RESPONSES IN CANCER PATIENTS“
11:30 PIERRE COULIE (UNIVERSITÉ CATHOLIQUE DE LOUVAIN, BRUSSELS, BELGIUM):
„MECHANISM OF TUMOR REGRESSION AFTER MAGE VACCINATION OF MELANOMA PATIENTS“
12:00 JEFFREY S. WEBER (USC/NORRIS COMPREHENSIVE CANCER CENTER, LOS ANGELES, CA, USA):
„IMMUNITY, AUTOIMMUNITY AND IMMUNE STIMULATING ANTIBODIES FOR THE TREATMENT OF MELANOMA“
12:30 LUNCH

SESSION 3: DENDRITIC CELLS AS ANTIGEN-PRESENTING CELLS

- 13:30 DEAN L. MANN (UNIVERSITY OF MARYLAND MEDICAL CENTER, BALTIMORE, MD, USA):
„4-TBB: A TARGET FOR ANTIBODY MEDIATED IMMUNOTHERAPY IN CML“
14:00 GEROLD SCHULER (UNIVERSITY HOSPITAL OF ERLANGEN, GERMANY):
„DENDRITIC CELL VACCINATION: FROM IMMUNOGENICITY TO CLINICAL RESPONSES“
14:30 A. KAROLINA PALUCKA (BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH, DALLAS, TX, USA):
„DC-BASED IMMUNOTHERAPY-WHICH SUBTYPE(S) SHOULD WE USE?“
15:00 COFFEE BREAK

SESSION 4: T-CELLS

- 15:30 JAMES P. ALLISON (MEMORIAL SLOAN-KETTERING CANCER CENTER, NEW YORK, NY, USA):
„BLOCKADE OF INHIBITORY SIGNALS - WHICH CHECKPOINTS SHOULD WE SELECT?“
16:00 JOHANNES W. VIEWEG (HEALTH SCIENCE CENTER, UNIVERSITY OF FLORIDA, FL, USA)
„STRATEGIES TO REVERSE TUMOR-MEDIATED IMMUNOSUPPRESSION“
16:30 RONG-FU WANG (BAYLOR COLLEGE OF MEDICINE, BAYLOR, TX, USA)
„CONTROL OF ANTITUMOR IMMUNITY AND TOLERANCE BY TLR SIGNALING AND REGULATORY T-CELLS“
17:00 RICHARD A. MORGAN (NATIONAL CANCER INSTITUTE, NIH, BETHESDA, MD, USA)
„TCR GENE THERAPY TRIALS IN HUMANS“

SOCIAL EVENING

SATURDAY APRIL 14, 2007

SESSION 5: NK/NKT/KILLER-DCs

- 09:00 VERONIKA GROH-SPIES (FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA, USA):
„THE ROLE OF NKG2D AND ITS LIGANDS IN TUMOR IMMUNITY AND AUTOIMMUNE DISEASE“
09:30 GUIDO J. TRICOT (MYELOMA INSTITUTE FOR RESEARCH AND THERAPY, UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, AR, USA):
„ADOPTIVE IMMUNOTHERAPY WITH HAPLOTYPE MISMATCHED NK CELLS: FIRST CLINICAL EXPERIENCE AND NEW WAYS TO IMPROVE OUTCOMES“
10:00 JAY A. BERZOFSKY (NATIONAL CANCER INSTITUTE, NIH, BETHESDA, MD, USA):
„TUMOR IMMUNOSURVEILLANCE: THE ROLE OF NKT CELLS“
10:30 COFFEE BREAK

